Leo sues Perrigo for patent infringement over skin gel
14-06-2016
Teva gets under Leo’s skin, knocks out two patents
06-10-2014
NicoElnino / iStockphoto.com
Denmark-based Leo Pharma and Californian rare disease company PellePharm have partnered to develop and commercialise therapies for rare forms of skin cancer.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Leo Pharma, PellePharm, collaboration, rare diseases, topical gel, Gorlin Syndrome, skin cancer, oncology,
